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Occidiofungin is a novel glycolipopeptide, synthesized and secreted by
Burkholderia contaminans MS14, demonstrating broad-spectrum antifungal activity and
potential for successful clinical applications. Its mechanism of action has not yet been
determined but is known to exhibit fungicidal activity via the induction of apoptosis in a
manner unique from that of currently approved antifungals. As an early investigation into
occidiofungin’s mechanism of action, we aimed to identify environmental and cellular
factors that significantly alter the susceptibility of the model organism, Saccharomyces
cerevisiae. To that end, we have demonstrated that occidiofungin’s bioactivity requires
active cellular growth, that new protein synthesis is necessary to adequately respond to
occidiofungin exposure, and that alterations in transcriptional regulation in response to
glucose and phosphate deprivation have synergistic and antagonist consequences,
respectively, on occidiofungin’s effectiveness. Together, this data provides a foundation
on which occidiofungin’s mechanism of action can be illuminated.
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CHAPTER I
INTRODUCTION

Invasive Fungal Infections
An Invasive Fungal Infection (IFI) is the infection of blood, normally sterile body
fluids, tissues, and organs by fungal organisms. These are typically classified as being
either endemic or opportunistic in nature, and their classification is an indication as to
how the infection was acquired (Pfaller and Diekema 2007). Endemic IFIs are associated
with exposure to a fungal pathogen in its natural environment, thus the causative
organisms vary according to geographical region. In the United States, endemic IFIs are
most commonly caused by Histoplasma capsulatum and Blastomyces dermatitidis in
southern and midwestern states, and by Coccidioides immitis in southern and western
regions (Chu, et al. 2006). The organisms of endemic IFIs capably infect
immunocompromised patients, but differ from their opportunistic counterparts in their
propensity to infect healthy hosts. One population-based study, conducted on a national
database of hospital inpatient stays in 2002, found that 13% of patients who died from
endemic IFIs were likely already at an increased risk of mortality due to serious
underlying conditions, while the remaining 87% were healthy and immunocompetent
prior to infection onset. This study also found a relatively low rate of mortality for
endemic IFIs, with crude mortality rates for children and adults at 5% and 7%,
respectively (Chu, et al. 2006). The same was not found for opportunistic IFIs.
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Opportunistic IFIs, most commonly caused by Candida spp., Cryptococcus
neoformans, Pneumocystis jirovecii, and Aspergillus spp., are of particular concern
because almost all are Healthcare Associated Infections (HAIs) (Pfaller and Diekema
2010). The Centers for Disease Control and Prevention (CDC) defines an HAI as “a
localized or systemic condition resulting from an adverse reaction to the presence of an
infectious agent(s) or its toxin(s) that was not present on admission to the acute care
facility” (The Centers for Disease Control and Prevention 2014). In order to more
accurately classify HAIs for epidemiological purposes, these infections are further
divided into two subclasses, Community-Onset (CO) and Healthcare Facility-Onset (HO;
formerly termed “nosocomial”), based on the period of time between a patient’s
admission to a healthcare facility and the onset of infection (before and after 72 hours
post-admission, respectively) (National Healthcare Safety Network (NHSN) Overview
2012).
The Epidemiology of Opportunistic Invasive Fungal Infections
The true presence of fungal infections is difficult to quantify, but improvements in
hospital reporting practices and the culmination of data from numerous studies has
provided a glimpse into their increasing epidemiological significance. One such study is
the National Hospital Discharge Survey (NHDS), a database compiled by the National
Center for Health Statistics consisting of inpatient data from roughly 500 nonfederal
acute care hospitals representatively distributed across all geographic regions in the U.S.
An analysis of this database found that, between 1979 and 2000, the rate of sepsis caused
by fungal organisms increased by 207%, greater than that of sepsis caused by grampositive or -negative organisms (Martin, et al. 2003). In 1996, the incidence of
2

hospitalization for invasive mycoses was 306 per million (Wilson, et al. 2002), and the
overall incidence of such infections has continued to rise (Alangaden 2011; Oren and
Paul 2014; Pfaller and Diekema 2010). Further, opportunistic IFIs are generally
associated with high mortality rates.
Numerous factors complicate resolving true case-fatality ratios. This is due to the
tremendous variations in patient age, health, prior exposure to risk factors, and
underlying conditions. However, studies using case-control methods are more accurately
able to determine the mortality rates due to IFIs by matching relevant background
information of patients with and without fungal infections and comparing the patients’
outcomes. Using this method, attributable mortality rates for candidemia (also called
invasive candidiasis [IC]), cryptococcosis, and invasive aspergillosis (IA) have been
estimated at between 10-49%, 21%, and 58%, respectively (Pfaller and Diekema 2010).
Even this method of analysis is inaccurate on some level, however, as a 2014 study
analyzing data from 11 single-center, multi-center, and nationwide reports on nearly
200,000 autopsies found that, of the 9,187 autopsies indicating the presence of IFIs, only
46% were diagnosed pre-mortem. This investigation revealed that much of the
epidemiological data based on the pre-mortem diagnosis of IFIs could be grossly
underestimated (Dignani 2014).
Regardless of the true epidemiological presence of IFIs, it is generally accepted
that this trend is – in part – due to, rather than in spite of, the development and more
widespread application of advanced medical and surgical procedures (Weinstein and
Fridkin 2005). Though these practices generally improve patient welfare, many of these
advances have increased the number of groups at-risk for the development of
3

opportunistic IFIs. The largest of these high-risk groups include those with previous
exposure to broad-spectrum antibiotics (due to a disruption of the host’s natural flora,
opening up formerly competitive growth environments to pathogenic organisms),
recipients of immunosuppressive therapy (particularly for cancer, hematopoeitic stem cell
transplants [HSCT] and solid organ transplants [SOT]), major surgery (especially those
involving the gastrointestinal [GI] tract), those with AIDS, neoplastic diseases, advanced
age, and premature birth (Procop and Roberts 2004; Weinstein and Fridkin 2005; Pfaller
and Diekema 2010; Alangaden 2011). These risk factors often leave the host extremely
vulnerable to pathogens that would otherwise be defeated by a healthy immune system.
With the increasing incidence of fungal infections, their association with high
mortality rates, and the growing size of populations at-risk, the fact that IFIs are a
tremendous financial burden on the U.S. healthcare system is not surprising. In 1998
alone, attributed costs for the treatment of systemic fungal infections were estimated to be
$2.6 billion, averaging $31,200 per patient and making up approximately 0.24% of the
total U.S. health expenditures for that year, an expense incurred by only 0.03% of the
total U.S. population. Further investigation found that the extended length of stay
required for many fungal infections was responsible for 47% of these costs, drug
expenses for 17%, laboratory tests 11%, and the remaining amount accounted for by
other factors (Wilson, et al. 2002). With such a significant portion of healthcare
expenditure dedicated to the treatment of fungal infections, the characterization of fungal
pathogens for use as model systems is an essential foundation for the development of
safer and more effective antifungals.

4

Candida and Candidemia
Of the approximately 600 fungal species known to be human pathogens, Candida
species are a valuable prospect for the characterization of fungal pathogenicity (Mayer,
Wilson and Hube 2013). This is largely due to the high mortality rate and frequency of
infections by Candida spp. in comparison to other fungal pathogens. As shown in Table
1.1, the incidence of infections by Candida spp. is comparable only to that of
Cryptococcus species – a pathogen with a relatively low case-fatality ratio – and far
exceeds the incidence of fungal infections with analogous mortality rates (Rees, et al.
1998). Candida’s identity as the most important cause of opportunistic mycoses is
supported by numerous other studies.
For example, studies evaluating the epidemiology of IFIs throughout various time
periods have consistently reported Candidemia (the presence of Candida species in the
blood) as the most prevalent of all systemic fungal infections, and for the last two
decades Candida species have remained the fourth leading cause of HO Bloodstream
Infection (BSI) in the United States, making up between 8-10% of all such BSIs
(Edmond, et al. 1999; Wisplinghoff, Bischoff, et al. 2004). Given that 10% of HO
infections are BSIs, and that a conservatively estimated 8% of those are candidemia,
Wenzel et al postulated that the annual number of HO candidemia cases ranges from
7,000-28,000. Considering that – according to data from the Surveillance and Control of
Pathogens of Epidemiologic Importance (SCOPE) – the crude mortality rate of
candidemia is 40%, Wenzel and colleagues estimated that 2,800-11,200 deaths per year
are associated with HO candidemia (Wenzel and Edmond 2001). Therefore, based on the
assumption that two-thirds of all Candida BSIs are HO, the number of candidemia cases
5

in the U.S. could range from 10,500-42,000 infections per year (Pfaller and Diekema
2007).
Table 1.1

Incidence and case-fatality ratios for selected fungal infections, San
Francisco Bay Area counties, 1992 – 1993 a
Incidence (no.
cases/million/yr) b

Pathogen
Candida species
C. albicans
Non-albicans
Cryptococcus
Coccidioides
Aspergillus
Histoplasma
Zygomycetes
Other
Total
a
b

Case-fatality ratio (%)

72.8
37.1
35.7
65.5
15.3
12.4
7.1
1.7
3.5
178.3

33.9
38.1
29.5
12.7
11.1
23.3
21.4
30.0
< 0.2
22.4

Data adapted from Rees et al. 1998.
Based on cases known to be the patient’s first episode of the infection.
The high occurrence of Candida infections thus places a much greater burden on

the U.S. healthcare system than other IFIs. Though the incidence of other major systemic
fungal infections – such as Invasive Aspergillus (IA) – appear to be decreasing, the
frequency of Invasive Candidiasis has remained steady over the past decade; and recent
data revealed that, with respect to IC, the risk of death during hospitalization is no lower
now than in the 1980s and early 90s (Pfaller and Diekema 2007). Furthermore,
hospitalization due to IC has been shown to increase the length of stay by an average of
14 days, burdening hospitals by limiting the space and personnel resources available to
care for other patients. The incidence, high mortality rates, and extended length of stay
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for treatment associated with IC (Table 1.2) translated to an estimated total cost of $1.7
billion in 1998 (65% of the total costs for systemic fungal infections in that year), at an
average per-patient additional cost of $14,804 (Wilson, et al. 2002). This financial burden
has continued to rise, with more recent studies indicating that the costs of IC average
$39,331 in additional expenses for adults and $92,266 for pediatric patients (Zaoutis, et
al. 2005).
These aforementioned factors have obligated clinical investigators to place great
emphasis on finding ways to reduce the burden of IC and other IFIs. The primary tactic
used is similar to that of the prevention of other HAIs: improved training of health care
workers (HCW) (Alangaden 2011). This strategy includes three simple, “low-tech”
practices: maximizing conformity to existing hand hygiene recommendations, improving
adherence to guidelines for the insertion and maintenance of central venous catheters, and
the rigorous enforcement of responsible antimicrobial application (Pfaller and Diekema
2007; Alangaden 2011). However, as indicated by the persistent incidence of IC
compared to other IFIs, reducing the infection rate of Candida spp. has proven
particularly difficult.

7

Table 1.2

Incidence and associated costs of candidiasis and other common invasive
fungal infections a
NHDS 1996

N

Rate per
million US
population

Candidiasis
Aspergillosis
Cryptococcosis

61,680
9,261
7,987

228.19
34.26
29.55

$14,804
$36, 867
$6,328

Histoplasmosis

3,681

13.62

$329

Incremental
costsb

LOSc
(days)

Total
82,608
305.62
$15,813
Wilson 2002.
b
average per-person hospitalization costs projected to 1998 dollars.
c
LOS – Length of Stay (excess hospitalization due to infection).
a

14
19

In-hospital
mortality
rate per
admission
6.3%
3.9%
16%
3.4%
6.8%

One reason for this resilience is that some Candida species, particularly Candida
albicans, are natural constituents of human microbial flora; thus, infections frequently
arise when these natural residents of the gastrointestinal tract gain an advantage over the
immune system of their host (Nucci and Anaissie 2001; Alangaden 2011). In fact, a
review of 203 published candidemia studies found 21 that evaluated specific sources for
Candida infections, and an analysis of these identified the gut as the primary endogenous
source for candidemia (Nucci and Anaissie 2001). For the remaining infections of
exogenous origin, the culprit could be any number of things, as Candida spp. have been
isolated from environmental cultures of various items in health care facilities such as
floors, countertops, other inanimate surfaces, and even food (Vazquez, Sanchez, et al.
1993; Vazquez, Dembry, et al. 1998). This seemingly omnipresent residency status in the
host and healthcare environments makes IC prevention understandably difficult. Thus,
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although the continued implementation of HAI prevention strategies is important, the
search and development of novel antifungal therapies through the use of established
model fungi is an essential step towards improving patient outcomes.
Two Yeasts in a Pod: Candida albicans and Saccharomyces cerevisiae
Of the more than 200 described Candida species, just 5 are responsible for the
majority of candidemia cases. As part of the ARTEMIS DISK Global Antifungal
Surveillance Study, data from 127 medical centers in 39 countries indicated that C.
albicans, C. glabrata, C. parapsilosis, C. tropicalis, and C. krusei were responsible for
90-95% of cases worldwide (Pfaller and Diekema 2007; Warnock 2007; Guinea 2014).
Of the 1,890 HO BSI Candida isolates identified in the SCOPE project between 19952002, C. albicans accounted for 54% of cases, with C. glabrata ranking second at 19%,
followed by C. parapsilosis and C. tropicalis at 11% each, and C. krusei at 2%
(Wisplinghoff, Bischoff, et al. 2004). Its prevalence makes C. albicans an exceptional
candidate for use as a model fungal pathogen and, as a result of such studies, much has
been discovered about its pathogenicity mechanisms and complex host-pathogen
relationship (Mayer, Wilson and Hube 2013). In addition to its prevalence in healthcare,
other factors have also strengthened its nomination as a model for IFIs. Particularly
notable is its similarity to one of the most extensively studied eukaryotic model
organisms, the budding yeast, Saccharomyces cerevisiae.
Saccharomyces cerevisiae, or Baker’s Yeast, has long been an integral part of the
continued pursuit to discover and understand the eukaryotic cell. Its single-cellular
nature, relatively quick replication cycle, and ease of handling/manipulation have
reinforced its continued use as a model eukaryote. From the early characterization of
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eukaryotic organelles and cellular trafficking, to the descriptions of interactions between
proteins and the mapping of entire regulatory cascades, the molecular techniques
perfected in S. cerevisiae ushered in entire new fields of study like “functional genomics”
and “systems biology”. Specifically, in April 1996, S. cerevisiae became the first
eukaryotic organism to have its entire genome sequenced. Like many studies before it,
what began in yeast has now expanded to more complex organisms, strengthening the
foundation of our current understanding of eukaryotic cell biology (Botstein and Fink
2011). The published sequence of its 16 chromosomes, encoding 6,604 open reading
frames, has enabled comparisons of functional genomics and evolutionary biology
studies between S. cerevisiae and numerous other organisms. The addition of this genetic
perspective has not only refined current phylogenetic tree models but also given a “headstart” to the genomic characterization of other organisms, particularly C. albicans
(Botstein and Fink 2011; Scannell, Butler, and Wolfe 2007). In fact, such studies on S.
cerevisiae and C. albicans have revealed that over 80% of the genes are similar between
both organisms (Kabir, Hussain and Ahmad 2012).
Both S. cerevisiae and C. albicans are members of the Saccharomycetaceae
family, characterized by reproduction via budding, within the Ascomycota (sac-fungus)
phyla of Fungi (Scannell, Butler and Wolfe 2007). These two yeasts share many qualities
including rapid growth, easy handling, dispersed cells, and replica plating. Additionally,
they frequently share certain aspects of many cellular signaling cascades. For example,
the Hog1 Stress-Activated Protein Kinase (SAPK) involved in sensing osmotic and
oxidative stresses is homologous between the two species, while the putative K+
transporter Kch1 involved in the ER stress response of both yeasts are merely orthologs
10

(Smith, Morgan, and Quinn 2010; Stefan and Cunningham 2013). Because of this close
relationship, many molecular technologies that have been discovered and perfected in S.
cerevisiae are directly transferrable to C. albicans after only small procedural
modifications (Kabir, Hussain and Ahmad 2012). These congruencies have continued to
support the role of C. albicans as a model for IFI pathogenicity. However, despite its
overarching prevalence in healthcare and likeness to S. cerevisiae, there are significant
limitations to using C. albicans that make S. cerevisiae more appropriate for initial
studies aimed at characterizing the Mechanism of Action (MoA) of novel antifungals. For
example, one key difference between the two organisms is the genetic complexity of C.
albicans.
Researchers in S. cerevisiae labs first began working with C. albicans around the
time when its identification as a microbial pathogen became increasingly common in the
1970s and 1980s, and even more began to study it in the ‘90s; but the chromosomal
instability and diploid nature of C. albicans greatly slowed the pace at which genetic
manipulation became readily feasible. Even with the publication of the complete genome
sequence of the C. albicans in 2004, progress was considerably slower than that of S.
cerevisiae, primarily due to the work required to make the C. albicans genome amenable
to manipulation. Hence, genomic studies have since experimentally verified the function
of only 1,403 genes (22.97% of its genome). Another 77.03% (4,705) of its genes’
functions have been assigned via comparative sequence analysis, but the remaining 152
genes/ORFs have yet to be characterized at all (Kabir, Hussain and Ahmad 2012).
Although select homozygous and heterozygous deletion mutants and regulated
expression strains are available for C. albicans, these libraries are incomplete
11

(McCluskey, Wiest and Plamann 2010). To the contrary, a complete library of unique
deletion mutants for every nonessential S. cerevisiae gene exists and is readily available.
This mutant library is a vital asset for studies on the bioactive mechanisms of antifungal
agents. Thus, the abundant similarities between the two organisms, combined with the
comprehensiveness of the S. cerevisiae mutant library, make it a comparable subject for
the wide-scale susceptibility testing required for antifungal MoA determination. Its
successful history as a research tool for other drugs also supports its continued use in this
regard (Cardenas, et al. 1999).
After the publication of the complete genome sequence of S. cerevisiae in 1996,
the scientific community’s understanding of conserved cell biology began improving
considerably. Of particular importance was the realization that the baker’s yeast has far
more in common with mammalian cells than previously thought. Though there are
expected differences, a surprising number of partially or completely conserved gene and
protein functions were discovered to exist between mammals and this yeast. In fact, at
least 31% of S. cerevisiae’s genes have homologs in humans (Botstein, Chervitz and
Cherry 1997). In instances where homologs do not exist, the ability to heterologously
express mammalian genes in S. cerevisiae has proved particularly useful. As such, it has
commonly (and successfully) been used to study genetic components of various human
diseases and the mechanisms of a wide array of drugs, including immunosuppressants
(cyclosporine A, FK506, and rapamycin) and steroid receptor antagonists (tamoxifen)
(Cardenas, et al. 1999). As discussed previously, S. cerevisiae also shares many features
with the pathogenic yeast, C. albicans (Goldstein and McCusker 2001). Its unique
relationship to both mammalian and fungal cells offers a unique opportunity, as S.
12

cerevisiae appears to stand in the middle ground between two distinct yet frequently
cohabitating organisms (Cardenas, et al. 1999). Using this concept as an advantage, it is
possible to identify cellular pathways in S. cerevisiae that, when altered, have an impact
on antifungal susceptibility. This information can subsequently serve as the groundwork
for describing an antifungal’s MoA. Additionally, characterizing the activity of
antifungals could highlight novel, fungi-specific targets and potentially open doors to the
development of entirely new classes of drugs.
Modern Antifungal Therapies
With such a significant impact on healthcare worldwide, fungal infections surely
deserve attention with regards to the research and development of effective antifungal
treatments. Unfortunately, antifungal research is a relatively young field and,
consequently, severely lacking in the variety of clinically available therapies. The first
antifungal agent, griseofulvin, was isolated in 1939 from a culture of Penicillium
griseofulvum dierckx, but its antifungal activity was not described until 1955, when it was
discovered to possess activity in vitro against pathogenic skin fungi. In 1958 it was found
that only oral administration was effective for the treatment of dermatomycoses.
Unfortunately, its activity was limited to this fungal group, making griseofulvin
unsuitable for treating systemic infections (Flint, Forsey and Usher 1959). Most of the
systemic antifungal drugs in use today were introduced after 1990, but the history of
these antifungals began with the discovery of amphotericin B in the 1950s (Nett and
Andes 2012). Amphotericin B’s potent and broad-spectrum activity led to its widespread
use against serious invasive fungal infections, but the dose-limiting toxicities associated
with its use illuminated the need for safer alternatives (Lewis 2011). Since, considerable
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progress has been made in antifungal therapy and there are now four classes of antifungal
drugs available for the treatment of systemic and invasive fungal infections. These
include Polyenes, Pyrimidine Analogs, Azoles, and Echinocandins. Their respective
cellular targets, spectrums of activity, bioavailability, toxicities, pharmacological
characteristics, and potentials for resistance development vary between and even within
classes, therefore all characteristics need to be considered when comparing the clinical
effectiveness (Nett and Andes 2012). Each class with their respective drugs and
characteristics are described in further detail below.
The Polyene Class
In the polyene drug class, amphotericin B (AmB) is the only molecule approved
for treating systemic fungal infections and is clinically available in four formulations
(Nett and Andes 2012). Its discovery in 1953 was a result of the broad screening of
Streptomycete cultures for antifungal activity. AmB possessed remarkable antifungal
activity but, in its pure form, had limited solubility in aqueous solutions at physiological
pH. It was determined that clinical use of AmB would require its association with another
molecule to facilitate clinical bioavailability, so a complex of AmB and sodium
deoxycholate was constructed that allowed for successful treatment by means of
intravenous infusion (Dutcher 1968; Laniado-Laborin and Cabrales-Vargas 2009).
Amphotericin B primarily kills yeast by binding ergosterol, but also has a secondary
mechanism wherein it permeabilizes the membrane by forming discrete channels through
which ions freely pass. This secondary effect is not required for AmB’s fungicidal
activity; instead, it is believed to increase the drug’s potency and the rate of fungal cell
death (Gray, et al. 2012). This dual-threat mode of action is a key factor in its broad
14

spectrum of activity. Because ergosterol is such a ubiquitous component of fungal cell
membranes, AmB possesses activity against a variety of fungi, including many
pathogenic yeasts, molds, and dimorphic species (White, Marr and Bowden 1998).
However, AmB’s partial affinity for cholesterol (ergosterol’s mammalian homolog) can
cause serious infusion-related side effects, most notably renal toxicity. This led to the
development of three AmB lipid conjugates in the late 1990s that, although less severe,
still possess similar infusion-related toxicities. Thus, lipid-based AmB preparations are
considered first-line treatment options and AmB deoxycholate as an alternative choice
(Nett and Andes 2012).
The Pyrimidine Analog Class
The Pyrimidine Analog class also contains just one approved drug. Flucytosine
(5-fluorocytosine; 5-FC) is a fluorinated cytosine analog first synthesized in 1957 as a
potential candidate for anti-tumor therapy (Duschinsky, Pleven and Heidelberger 1957).
Though its effectiveness as a cancer drug was limited (Heidelberger, et al. 1958), it was
soon discovered to possess activity against Candida spp., Cryptococcus neoformans, and
fungi causing chromoblastomycosis (a fungal infection of the skin) (Benson and Nahata
1988). Flucytosine is approved for use as an oral capsule, with bioavailability of the drug
remarkably high (between 80-90%) (Schönebeck, et al. 1973). Interestingly, 5-FC
possesses no antifungal activity in its native form; rather, fungal uptake of the molecule
by cytosine permease allows for subsequent intracellular conversion to 5-fluorouracil (5FU) via cytosine deaminase. This molecule is then further converted to two additional
active metabolites that inhibit RNA and DNA synthesis (Waldorf and Polak 1983). There
are multiple factors limiting 5-FC’s successful use as an antifungal. First, dependence on
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cytosine deaminase for 5-FC sensitivity is a major limiting factor in its spectrum of
activity, as fungi lacking this enzyme are obviously unable to convert the inactive 5-FC to
its active metabolite (A. Polak 1977). Further, this limitation cannot be circumvented
through the direct use of 5-FU because of its severe toxicity to mammalian cells and
limited uptake of 5-FU by fungi (Polak and Grenson 1973). Second, the intrinsic
resistance of many strains and the frequent occurrence of resistance during treatment
further complicate the use of 5-FC. Consequently, 5-FC is not typically utilized as a
monotherapeutic agent, but rather co-administered with other antifungals such as AmB
(Vermes, Guchelaar and Dankert 2000).
The Azole Class
Azoles are the most abundant class of antifungals, with at least 9 different drugs
approved for the treatment of either topical or systemic fungal infections. These drugs are
characterized by the presence of a five-membered heterocyclic ring that contains one or
more additional atoms (either nitrogen, sulfur, or oxygen). In the case of antifungal
azoles, they contain either two or three nitrogens and are termed imidazoles or triazoles,
respectively (Sheehan, Hitchcock and Sibley 1999). The imidazoles (apart from
ketoconazole) are only used as superficial antifungal therapies. Triazoles, on the other
hand, are used to treat a variety of superficial and systemic fungal infections and also
show greater specificity for fungal cells versus those of the host, making them much safer
in comparison. Regardless of their structure or effective use, azole antifungals function
by interfering with the synthesis of ergosterol via inhibition of the enzyme, lanosterol
demethylase. This enzyme, also called 14-sterol demethylase (encoded by the ERG11
gene), is a cytochrome P450-dependent component of the ergosterol synthesis pathway,
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and its inhibition results in the depletion of total ergosterol and a buildup of the enzyme’s
usual substrate, 14-methylated sterols. Ergosterol is both the major sterol of the fungal
cell membrane (and therefore essential for membrane integrity and fluidity) and a vital
component in nutrient transport and chitin synthesis. Further, trace amounts of ergosterol
are required, as it serves a “sparking” function to allow progression through the cell cycle
(Sheehan, Hitchcock and Sibley 1999). Because their MoA results in inhibited growth
and altered membrane structure and function, azoles are merely fungistatic in their
activity. Thus far, four mechanisms of azole resistance have been described in Candida
species. These mechanisms involve the induction of efflux pumps that reduce
intracellular drug concentrations, point mutations in the ERG11 gene that reduce drug
affinity, upregulation of lanosterol 14-alpha-demethylase (thereby increasing the azole
concentration required for effect), or the development of bypass pathways in which the
membrane-disruptive effects of azoles are circumvented. Strains resistant to azoles may
possess one or more of the above mutations (Pfaller 2012). Like most antifungals, azoles
are typically administered in combination with other therapeutic agents to improve
therapy effectiveness and reduce the likelihood of resistance development.
The Echinocandin Class
Echinocandins are the newest and final class of antifungal drugs approved for the
treatment of systemic infections. The FDA approved the first agent, caspofungin, in 2002,
and two additional class members, micafungin and anidulafungin, were subsequently
approved in 2005 and 2006, respectively. Echinocandins are semisynthetic, cyclic
hexapeptides that are N-linked to a fatty acyl side chain (Perlin 2011). While polyenes
and azoles target the cell membrane, echinocandins possess concentration-dependent
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antifungal activity via strong inhibition of ß-1,3-D-glucan synthase, which synthesizes the
cell wall biopolymer ß-1,3-D-glucan (Pfaller 2012). This enzyme is composed of two
subunits, Fks and Rho. The Rho subunit is a GTP-binding protein and regulates ß-1,3glucan synthase activity. The catalytic activity of enzyme is contributed by Fks (encoded
by the FKS1, FKS2, and FKS3 genes) and is the target of echinocandins. Though the
exact mechanics of the echinocandin–glucan synthase interaction are unclear, studies
have indicated that enzymatic removal of the aliphatic tail results in the drug’s
inactivation. It is also unknown whether the activity of echinocandins is dependent upon
transport into the cell, but it is hypothesized that the tail inserts itself into the lipid bilayer
of the cell membrane and carries out its inhibitory affects from the extracellular side
(Perlin 2011). Regardless of the exact mechanism, echinocandins have rapidly become
the preferred treatment against a number of fungal pathogens (Perlin 2011). This is partly
due to their specificity for impact on the fungal cell wall – a target conveniently absent
from mammalian cells – making it a relatively low-risk therapy. This, combined with a
lack of cross-resistance potential with other antifungals and their activity against
susceptible Candida spp. and Aspergillus spp., equates to a favorable therapeutic index.
Though echinocandins are fungicidal against yeast and even azole-resistant Candida
strains, their activity against molds like Aspergillus spp. is fungistatic. Although clinical
failure as a result of echinocandin resistance in susceptible species like Candida is
unusual, isolates with reduced susceptibility to these drugs are being identified with
increasing frequency (Perlin 2011). Resistance is typically associated with mutations in
two highly conserved regions of FKS1 and/or FKS2 that result in amino acid substitutions
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in the Fks subunit; these mutations generally impart cross-resistance among the
echinocandin class (Perlin 2011).
The Need for Novel Antifungal Therapies
With the limited treatment diversity, various associated toxicities, and increasing
occurrences of antifungal resistance in already-prevalent fungal strains, great emphasis
has been placed on the discovery of novel antifungal agents to fill the gaps in, and
improve, current therapy options.
Occidiofungin, a Novel Antifungal
Occidiofungin is a novel cyclic glycolipopeptide demonstrating great potential for
clinical antimycotic application as a broad-spectrum antifungal agent. The soil bacterium
Burkholderia contaminans MS14 synthesizes the peptide via nonribosomal peptide
synthetases and secretes it into the surrounding environment, thus it was first recognized
to have antifungal activity as a result of the bacteria’s suppression of a fungal turf grass
disease, Brown Patch (Lu, et al. 2009). Structural analysis revealed two closely related
variants, occidiofungin A (1199.55 Da) and B (1215.55 Da). Both possess a cyclic
structure composed of eight amino acids, one of which is ß-hydroxy tyrosine and another
is an 18-carbon novel fatty amino acid. This novel fatty amino acid contains a small acyl
group and functions as an attachment point for a xylose sugar. The two variants differ
only in the addition of an oxygen atom to occidiofungin B’s asparagine (forming ßhydroxy asparagine), which explains the slight difference in mass.
A 56kb genomic DNA region containing 16 genes, now termed the occidiofungin
gene (ocf) cluster, is responsible for occidiofungin’s biosynthesis in B. contaminans
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MS14 and has been described (Gu, Smith and Liu, et al. 2011). Further analysis of this
genetic and biochemical map demonstrated that the ocfC gene, which encodes a
glycosyltransferase, is responsible for the addition of xylose to occidiofungin. After
examining the antifungal activity of the ocfC gene mutant, MS14KC1, it was determined
that presence of xylose is not important for occidiofungin’s bioactivity (Chen, et al.
2013).
Additional research conducted on the chemical stability and in vitro activity have
revealed that occidiofungin retains the full potency of its activity after exposure to not
only extreme pH ranges (2-9) and high temperatures (100°C), but also after incubation
with gastric proteases. These findings suggest that occidiofungin may be suitable for oral
administration, as these parameters are representative of the environments the drug will
encounter in the GI tract. This is significant because the only currently available oral
therapies are azole-class antifungals, to which a growing number of Candida spp. strains
are acquiring resistance (Ellis, et al. 2012). Also supporting occidiofungin’s potential for
clinical use are recent studies conducted on its toxicity in a mammalian system. These
studies revealed that a single dose as high as 20 mg/kg in mice did not affect
hematological or serum biochemistry, and additional experiments using lower, repeated
dosing returned similar results. This indicates that occidiofungin administration may not
result in substantial alterations in organ function. Though initial examinations reveal a
low potential for toxicity, the researchers did note that further investigation was vital to
completely characterize the range of occidiofungin’s pharmacological effects (Tan, et al.
2012).
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Although its exact mechanism of action is not fully understood, studies indicate
that occidiofungin possesses broad-spectrum activity against fungi and exhibits its effects
via a mechanism unique from currently available antifungals. Thus far, Minimum
Inhibitory Concentration (MIC) assays have determined that occidiofungin’s activity is
not reliant on disruption of the plasma membrane or other lytic pathways, the binding of
ergosterol, or the activity of β-1,3-glucan synthase. Further, occidiofungin exposure does
not appear to impact cell cycle progression (Emrick, et al. 2013). Occidiofungin does,
however, impart morphological changes on fungal cells at subinhibitory concentrations,
as cells analyzed after exposure to such doses demonstrated reduced coat (manno)
proteins on the outer cell wall, possessed intracellular inclusions, and had an enhanced
distribution of chitin (primarily at emerging bud tips) in daughter cells (Emrick, et al.
2013). Additionally, occidiofungin appears to induce damage to the cell wall, as indicated
by the activation of the Cell Wall Integrity pathway as soon as 10 minutes after exposure.
However, occidiofungin’s fungicidal activity is primarily via apoptosis due to the
increased production of reactive oxygen species (ROS), double stranded DNA breakage,
and the externalization of phosphotidylserine that occurs upon exposure to lethal
occidiofungin concentrations. Further, under anaerobic conditions (an environment
known to reduce the production of ROS), the MIC of the wild type and mitochondrially
dysfunctional yeast was double that of typical conditions, suggesting ROS may play a
significant role in supporting occidiofungin’s MoA. Further supporting an apoptotic
mechanism of action is the two-fold increase in the occidiofungin concentration required
to inhibit growth in the YCA1 gene mutant. This gene encodes a caspase-like cysteine
protease responsible for, among other things, regulating apoptosis in response to high
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levels of reactive oxygen species (Emrick, et al. 2013). The role of another apoptosisassociated gene, NDE1 (encoding for a mitochondrial external NADH dehydrogenase),
was assessed via MIC analysis and the deletion strain was found to be 2-fold more
sensitive than the wild type. Other apoptotic mutants exhibiting resistance to
occidiofungin include those deleted for RNY1, a gene encoding a vacuolar RNase that
promotes apoptosis under oxidative stress, and CSG2, a calcium regulatory protein
involved in the biosynthesis of sphingolipids. Due to the considerable amount of crosstalk between apoptotic and autophagic pathways, various autophagic mutants were also
assessed via MIC, but none suggested a role for autophagy in occidiofungin-induced cell
death. Thus, apoptosis appears to be the cause of death in occidiofungin exposure.
Objectives and Experimental Design
In this study, our goal is to further characterize occidiofungin’s bioactivity by
comparing the susceptibility of yeasts to occidiofungin under a variety of environmental
conditions. In this way, we hope to identify cellular pathways that, when their regulation
is altered in response to these conditions, have an impact on occidiofungin’s bioactivity.
By categorizing pathways as having a positive, negative, or neutral impact on
susceptibility, we will establish a number of directions in which research on this novel
antifungal can confidently progress.
To accomplish this, we will utilize Colony Forming Unit (CFU) assays using sublethal concentrations of occidiofungin. Though the Minimum Inhibitory Concentration
(MIC) assay is the standard tool for determining antifungal resistance in the clinical
setting, we have found that its results have limited utility with regards to detecting subtle
variances in susceptibility. By design, the MIC assay allows for the determination of the
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minimum concentration of an antimicrobial agent required to inhibit the visible growth of
a microorganism. This is in contrast to a Minimum Lethal Concentration (MLC) assay, in
which the data reported indicates the minimum concentration required to kill a
microorganism. In the context of occidiofungin with regards to MIC and MLC values,
occidiofungin’s fungicidal activity renders the two values equal, meaning that yeasts are
either killed by the drug or survive unscathed. Additionally, both assays report results
after overnight incubation. Thus, a single yeast surviving exposure to a particular
concentration of occidiofungin in these assays may be able to proliferate to detectable
levels, therefore impacting the reported values. Consequently, for our purposes,
MIC/MLC values are insufficient in reporting whether certain strains or environmental
conditions lend yeasts more or less vulnerable to occidiofungin. The CFU assay,
therefore, has been selected due to its increased sensitivity and ability to monitor cell
viability over a period of hours instead of days. Additionally, our goal of detecting subtle
variances in susceptibility led us to conduct CFU assays using sub-lethal concentrations
of occidiofungin, as lethal concentrations would leave no surviving cells and lend our
assay no more useful than an MIC.
Cellular Pathways Examined in This Study
Due to our interest in using altered environmental conditions to induce
transcriptional changes in the yeast cell, it is important to establish which pathways are
responsible for sensing and responding to these altered conditions. In this regard,
important pathways involved in nutrient sensing are described below.
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Quiescence
Like most living cells, yeast are capable of exiting the cell cycle and entering an
alternative resting state called quiescence. Early studies described quiescence as a single
G0 state of the cell cycle, initiated by the prolonged deprivation of nutrients regardless of
the specific environmental conditions in which the cell was placed. These studies were
conducted on cells grown to saturation in rich media, and the results described particular
characteristics that came to define quiescence, namely resistance to heat-shock and
oxidative stress, thickened cell walls, and altered transcriptional profiles (Gray, et al.
2004). Recent work by Klosinska et al, however, has indicated that only a small subset of
genes is consistently associated with quiescent cells independent of the specific nutrient
for which the cell is starved. The remaining transcriptional changes appear to reflect
compensation for the declining availability of specific nutrients. For instance, the
upregulation of genes involved in vacuolar transport and autophagy allows the cell to
recycle existing proteins and organelles upon starvation for nitrogen in order to reallocate
its limited resources (Klosinska, et al. 2011). Based on these findings, it was proposed
that quiescence is not a single, distinct phase of the cell cycle, but rather a limited set of
discrete cellular programs tailored to improve survival under specific stresses
encountered by the cell. Further, it was illustrated that most of the stress-resistant
properties associated with quiescence are simply extensions of those found in slow
growing cells (Klosinska, et al. 2011). Additionally, apart from the detection of a carbon
source (the presence of which is a primary and sufficient stimulant for cell cycle reentry)
quiescent yeast are also capable of responding to changes in their environment, such as
irradiation, heat shock, oxidative stress, and exposure to certain chemicals and toxins, and
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do so by altering the transcription of genes just as actively proliferating yeast do (Gray, et
al. 2004). For these reasons, it is desirable to assess the bioactivity of occidiofungin in
quiescent cells, as establishing whether active cellular growth or normal physiological
processes are required for its activity could be an important indicator as to its mechanism
of action.
Nutrient Signaling and the Cellular Response to Starvation Conditions
Nutrient sensing and signaling mechanisms related to nutrient-controlled cellular
regulation have been well characterized in yeast. Most of these pathways are regulated
using the nutrient itself as an indicator, and these nutrients have been shown to modulate
numerous signaling cascades associated with their transport and metabolism. For
example, glucose is the preferred fermentable carbon source for S. cerevisiae and serves
as the key signaling molecule in a variety of cellular pathways. Some of these pathways
are involved in catabolic repression and serve to conserve resources by suppressing
alternative metabolic pathways when a more favorable energy source, like glucose, is
available (Conrad, et al. 2014). The presence of glucose also regulates other pathways,
such as those involved in repressing stress tolerance mechanisms and stimulating cell
proliferation. By using glucose as the central signal for these regulatory cascades, the cell
is able to mount a whole-cell transcriptional response appropriate for the availability of
glucose. This theme is central to other nutrient-dependent cellular responses, such as the
phosphate-regulated PHO pathway (Conrad, et al. 2014).
Additionally, although the deprivation of particular nutrients impacts regulatory
pathways specific to their reacquisition, broader signaling cascades responsible for
synchronizing cellular processes to nutrient availability are also activated. For example,
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the Target of Rapamycin (TOR) kinases play an important role in regulating the
transcriptional response to nutrient availability (Aronova, et al. 2007). As the name
suggests, it was first discovered as the target of the inhibiting drug, rapamycin. Upon
exposure to rapamycin, cells exhibited significant alterations in physiology similar to the
starvation response, thus providing the first indication of TOR’s role in the cell.
Saccharomyces cerevisiae have two TOR kinases, Tor1p and Tor2p, which associate with
other proteins to form the TOR1 Complex (TOR1C). This complex is responsible for
regulating cellular growth in response to the availability of extracellular nutrients, and its
inhibition by rapamycin mimics the native response to nutrient deprivation (Aronova, et
al. 2007). Although the exact manner in which nutrient levels are communicated to TOR
remains to be described, the varying branches of the TOR pathway provide an
opportunity to identify transcriptional profiles in the cell that, when altered, might have
an impact on the bioactivity of antifungals. Though our early studies using MIC assays
indicated that the deletion of tor1 had no impact on occidiofungin bioactivity (data not
shown), characterizing occidiofungin activity as it pertains to nutrient-specific
transcriptional responses could reveal further paths to pursue.
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CHAPTER II
MATERIALS AND METHODS

Strains, Media, and Reagents
All yeast strains used in this study are derivatives of Saccharomyces cerevisiae
BY4741, obtained from Thermo Fisher Scientific, and are listed in Table 2.1. The
CIT2:HA3::HIS3 strain was constructed as reported previously by Ünlü and colleagues
(Ünlü, Narayanan and Gordon 2013). All media preparations (Table 2.2) were conducted
using previously published protocols (Sherman 1991). A working dilution of
occidiofungin at 0.4mg/mL in 100% DMSO was prepared from the 1mg/mL stock
solution. Rapamycin (Sigma) was prepared at 1mg/mL in 100% ethanol. Cycloheximide
(Sigma) was prepared at 10mg/mL in sterile distilled water. Chloramphenicol (Sigma)
was prepared at 34mg/mL in 100% ethanol.
Table 2.1

Saccharomyces cerevisiae strains used
Mutant Strain *

Systematic Name

∆tor1::KanR

YJR066W

CIT2:HA3::HIS3

YCR005C

∆pho4::KanR

YFR034C

∆pho80::KanR

YOL001W

* all strains are derivatives of S. cerevisiae BY4741, having the
genetic background MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0
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Table 2.2

General preparation of media

Media

Components

YPD

+ 10g Bacto™ Peptone
+ 5g Bacto™ Yeast Extract
^ distilled water to 475mL
Autoclave 28 minutes @ 121°C
+ 25mL 40% Glucose

YPD agar plates

+ 10g Bacto™ Agar
+ 10g Bacto™ Peptone
+ 5g Bacto™ Yeast Extract
^ distilled water to 475mL
Autoclave 28 minutes @ 121°C
+ 25mL 40% Glucose

Depleted YPD

A 25mL culture of wild-type yeast were grown
to saturation in YPD at 30°C with shaking for 5
days. Depleted YPD media was obtained by
passing the culture through a 0.2µm filter to
remove yeast prior to use.

Synthetic Defined

+ 0.85g Yeast Nitrogen Base

(Minimal Complete)

(w/o amino acids and ammonium sulfate)
+ 10g Glucose
+ 2.5g Na 2SO4
+ 2.5g (NH 4)2SO4
+ 0.01g Histidine
+ 0.04g Leucine
+ 0.01g Methionine
+ 0.01g Uracil
^ distilled water to 500mL
Autoclave 23 minutes @ 121°C

SD –Glucose

SD media was prepared as previously described,
without the addition of glucose.

SD –Nitrogen

SD media was prepared as previously described,
without the addition of ammonium sulfate
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Table 2.2 (continued)
SD –Phosphate

+ 0.85g Yeast Nitrogen Base
(w/o amino acids and ammonium sulfate)
+ 2.5g Na 2SO4
+ 2.5g (NH 4)2SO4
+ 5mL 1M MgSO 4
+ 10mL 29% NH 4OH
^ distilled water to 500mL
• Mix 1 hour @ RT
• Filter 2X through Buchner Funnel
+ 10g Glucose
+ 0.01g Histidine
+ 0.04g Leucine
+ 0.01g Methionine
+ 0.01g Uracil
• Autoclave 23 minutes @ 121°C
(Kaneko, Toh-e and Oshima 1982)

SD Complete +Glutamate

+ 0.85g Yeast Nitrogen Base
(w/o amino acids and ammonium sulfate)
+ 10g Glucose
+ 2.5g Na 2SO4
+ 2.5g (NH 4)2SO4
+ 0.05g Glutamic Acid
+ 0.01g Histidine
+ 0.04g Leucine
+ 0.01g Methionine
+ 0.01g Uracil
^ distilled water to 500mL
Autoclave 23 minutes @ 121°C

SD +2% Raffinose

SD Media was prepared as previously
described, with the addition of 10g raffinose
substituted for glucose.
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Colony Forming Units (CFU) and Spotting Assays
For each condition tested, unless otherwise noted, cells were removed from a
culture in mid-log phase of growth (~0.5 OD600) via centrifugation (13,000 x g for 8
minutes at 4°C) and resuspended in the appropriate media at a final cell density of 0.5
OD600, or approximately 1.67 x 107 cells/mL. At indicated time points, 200µL of cells
were transferred to the first column on a 96-well microtiter plate. Each sample was then
5-fold serially diluted 7 times by transferring 40μL cells from one column into the next
well containing 160μL of the same media. Depending on the viscosity of the media,
between 3.0 – 4.0µL from each well was spotted in profile onto a 150mm YPD plate and
then incubated at 30°C. Multiple images were recorded between 24 and 48 hours of
incubation. To determine colony-forming units (CFU), 50µL from select dilutions were
spread, in duplicate, onto 100mm YPD agar plates. Colonies were counted after 48 hours
of incubation at 30°C. Only data from plates that had between 30 and 300 colonies were
used in determining CFUs. The CFU value for each sample was calculated using the
following formula:
CFU = N × 20 × 5D–1

(Equation 2.1)

where N = # colonies on plate and D = column # of the corresponding dilution
For all samples, the Mean CFU at each indicated time point was determined, and
its value was plotted as the Log10 (Average CFU) versus time (hours).
For instances in which samples were treated with occidiofungin, cells were treated
with 1μg/mL occidiofungin, indicated by “+occ”, and that sample’s counterpart treated
with an equivalent volume of vehicle control, indicated by “Ø” (theta). Samples were
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treated immediately after the dilutions at T0 hours and then incubated at 30°C with shaking
for the indicated duration of the experiment.
Where indicated, samples were pre-treated with either 25µg/mL cycloheximide or
60µg/mL chloramphenicol, or their vehicle controls (sterile distilled water or 100%
ethanol, respectively). In these instances, all samples were prepared simultaneously and
those which were selected for pre-treatment (as indicated) received one of the
pharmacological agents while untreated samples received the appropriate vehicle
control(s). All samples were incubated at 30°C with shaking for 30 minutes followed
select samples (as indicated) being treated with one of the drugs immediately prior to the
T0 CFU dilution. Appropriate samples were subsequently treated with occidiofungin or its
control, as indicated and described above.
Preparation of Quiescent Cells and Verification of the Quiescent Cell State
A quiescent culture was obtained by growing wild type cells in 25mL YPD at
30°C with shaking for 4 days. To verify quiescence, resistance to oxidative stress and
elevated temperatures was tested as previously described (Klosinska, et al. 2011).
Briefly, to assess resistance to oxidative stress, 1mL aliquots of cells were subjected to
0mM, 1mM, 5mM, 10mM, and 50mM hydrogen peroxide for 1 hour at 30°C. Cells
were subsequently diluted in YPD (unless otherwise noted) to 1.67 x 107 cell/mL and a
200µL aliquot from each sample was 5-fold serial diluted in YPD in a 96-well microtiter
plate in the same manner as described in “Colony Forming Units (CFU) and Spotting
Assays”. 3.75µL of each dilution was spotted, in profile, onto a 150mm YPD plate. A
similar treatment and dilution protocol was followed in parallel for cells from an
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exponentially growing culture. Plates were incubated at 30°C and images recorded
between 24 and 48 hours to compare cell viability.
To test resistance to elevated temperatures, 1mL aliquots of both quiescent and
exponentially growing cells were subjected to temperatures of 50°C, 53°C, and 55°C for
0, 5, 10, and 20 minutes. Cells were diluted to 1.67 x 107 cells/mL in distilled water and a
200µL aliquot from each sample were 5-fold serial diluted in YPD in a 96-well microtiter
plate, as previously described. 3.75µL of each dilution was spotted, in profile, onto a
150mm YPD plate. Plates were incubated at 30°C and images recorded between 24 and
48 hours.
Percent Cell Viability with Exposure to Elevated Temperatures
A mid-log culture was prepared as outlined above. As described above, a
quiescent culture was prepared and split into a control and fresh media group. Samples of
each group were prepared simultaneously by pelleting via centrifugation (13,000 x g for 8
minutes at 4°C) and subsequent resuspension in media to a cell density of 0.5 OD600. The
mid-log and quiescent fresh media samples were resuspended in fresh YPD while the
quiescent control sample was resuspended in Depleted YPD. At the start of the
experiment (T0hours), 1mL of cells from each culture was exposed to 53°C for 10 minutes
and a volume equivalent to 1x105 cells was diluted with YPD in a microtiter plate, as
previously described. Following the same protocols outlined above, Spotting and CFU
Assays were carried out. Cultures were incubated at 30°C with shaking for the duration
of the experiment and the assays repeated after 0.5, 1, and 2 hours of exposure to the
media. Percent cell viability was calculated at the indicated time points by dividing each
sample’s post-heat treatment CFU value by the untreated CFU value of the same sample.
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Western Blot Analysis
Total cellular protein was extracted by alkaline cell lysis followed by TCA
precipitation and then solubilized in SDS-PAGE loading buffer via bath sonication
(Riezman, et al. 1983). For western blot analysis, protein samples equivalent to 0.1 OD600
of original cell culture were separated by SDS-PAGE and transferred to nitrocellulose.
After staining the membrane with amido black to visually confirm equal loading, the
membrane was blocked with 1X TBS-Tween (20mM Tris pH 7.4, 200mM NaCl, 0.1%
Tween-20) supplemented with either 2% BSA or 5% non-fat dry milk. Protein detection
was conducted using murine primary antibodies at 1:5,000 (HA3; Covance) and 1:20,000
(Pgk1p; Invitrogen) dilutions and an HRP-conjugated anti-murine secondary antibody
(GE Healthcare) at a 1:8,000 dilution. Pierce enhanced chemiluminescence detection
system from Thermo Scientific was used for detection.
Antifungal Preparation
The occidiofungin used in this study was a gift from James Leif Smith,
Department of Biology, Texas A&M University and was isolated as previously described
(Gu, Smith and Wang, et al. 2009). In summary, Burkholderia contaminans strain MS14
was cultured in potato broth at 28°C for 7 days without shaking. The culture extract (cell
free) was precipitated using 50% weight/volume ammonium sulfate and the resulting
pellet resuspended in 35% acetonitrile (ACN):water (volume/volume) and further
purified by Reversed-Phase High Performance Liquid Chromatography using a 4.6 ×
250mm C18 column (Grace-Vydac). Aliquots of lyophilized occidiofungin were
resuspended in 100% DMSO to generate a 1mg/mL stock.
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CHAPTER III
RESULTS

Quiescent Yeast Exhibit Resistance to Occidiofungin
Due to the similarities between quiescent and slow growing yeast, it was desirable
to characterize the susceptibility of quiescent cells to occidiofungin exposure. To verify
that the yeasts had reached a quiescent state by the four day incubation period, their
resistance to oxidative stress and elevated temperatures was assessed. As shown in Figure
3.1, exponentially growing cells were markedly more susceptible to oxidative stress than
quiescent yeast. A similar sensitivity profile was obtained when elevated temperature was
used as the stressor (Figure 3.2). Therefore, retention of cell viability for the quiescent
culture after exposure to oxidative stress and elevated temperatures confirmed that these
cells were in quiescence.

34

Figure 3.1

Quiescent cells exhibit resistance to oxidative stress

Depiction of differences between mid-log and quiescent cells in resistance to oxidative
stress. An aliquot of cells from mid-log and quiescent cultures were incubated at 30°C in
0mM, 1mM, 5mM, 10mM, and 50mM H2O2 for 1 hour prior to 5-fold serial dilution and
spotting. Representative image shown (n=2).

Figure 3.2

Quiescent cells exhibit resistance to elevated temperatures

Depiction of the differences between mid-log and quiescent cells in resistance to elevated
temperatures. Aliquots of 1mL cells from mid-log and quiescent cultures were subjected
to 50°C and 55°C for 0, 5, 10, and 20 minutes. 200µL from each was five-fold serial
diluted 7 times and 3µL were spotted, in profile, onto a 150mm YPD agar plate.
Representative image shown (n=2).
To determine if these differences in cell viability impact susceptibility to
occidiofungin, the sensitivity of quiescent cells was compared to that of mid-log phase
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cells by Colony Forming Unit determination (CFU; Figure 3.3) and Spotting Assay
(Figure 3.4). The data confirm that quiescent cultures were resistant to occidiofungin
compared to actively growing cells during the first hour of exposure. However, cells
maintained in culture for a longer period of time showed a decline in viability, likely due
to cells exiting their quiescent state and reentering the cell cycle in response to newly
available carbon source.

Figure 3.3

Quiescent cultures exhibit temporary resistance to occidiofungin in fresh
YPD

Graph illustrating the temporary resistance of quiescent cells compared to mid-log in
YPD with 1.0µg/mL occidiofungin (+occ). Representative graph shown (n=2).
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Figure 3.4

Quiescent cells exhibit temporary resistance to occidiofungin in fresh YPD

Mid-log and quiescent cells – after treatment with 1.0µg/mL occidiofungin (+occ) or an
equivalent volume of 100% DMSO control (Ø) for the indicated time – were 5-fold
serially diluted in YPD in a microtiter plate and 4.0µL from each dilution were spotted, in
profile, onto a YPD agar plate. Representative image shown (n=2).
To further characterize the initial resistance and subsequent decline in cell
viability, the same experiment was conducted with the addition of “depleted” YPD media
(see “Materials and Methods”) to determine the effects decreased nutrient availability had
on occidiofungin bioactivity in both cell types. As seen in Figure 3.5, quiescent cell
viability trends in fresh YPD were similar to previous findings: cells exhibited an initial
resistance to occidiofungin followed by a decline in cell number. Quiescent cultures in
depleted media, however, maintained almost complete resistance to occidiofungin up to 4
hours post-exposure. Interestingly, mid-log phase cells were significantly more
susceptible to occidiofungin in depleted YPD than in the fresh media control.
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Figure 3.5

Nutrient availability has a significant impact on susceptibility to
occidiofungin

Graph illustrating mid-log and quiescent cells in new and depleted (depl.) YPD with
1.0µg/mL occidiofungin (+occ). Representative graph shown (n=2).
The delayed susceptibility of quiescent cells to occidiofungin is of particular
interest. Given that the biological target of occidiofungin has yet to be identified, it is
important to characterize the shift from resistant to susceptible that occurs when
quiescent cells are exposed to occidiofungin in fresh media, as it may aid in uncovering
the mechanism by which occidiofungin induces cell death. To monitor the transition from
a quiescent to actively growing state, the assay comparing % Cell Viability after exposure
to elevated temperatures was repeated with the addition of a quiescent cell sample placed
in fresh YPD media (as described in the Materials and Methods). As shown in Figures 3.6
and 3.7, quiescent cell resistance to high temperatures declined over time when cells were
introduced to fresh media and approached that of actively growing cells within 2 hours.
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Figure 3.6

Quiescent cells approach mid-log levels of sensitivity to elevated
temperatures (53°C) in fresh YPD with respect to time

This graph indicates the percentage of viable cells remaining after 10 minutes of
exposure to 53°C, relative to unexposed cells, with respect to the indicated time
maintained in fresh YPD (“mid-log” and “quiescent + fresh YPD” samples) or depleted
YPD (“quiescent” sample). Representative graph shown (n=3).
The loss of resistance to elevated temperatures is indicative of cells exiting their
quiescent state and resuming proliferative growth. This is in support of the notion that
yeasts are protected from occidiofungin as long as they remain in quiescence.
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Figure 3.7

Quiescent cells placed in fresh YPD lose their resistance to elevated
temperatures (53°C) over time

Spotting Assay depicting cell viability of mid-log cells in YPD, quiescent cells in their
culture medium, and quiescent cells in fresh YPD for 0, 1, and 2 hours prior to exposure
to 53°C for 10 minutes. Representative image shown (n=3).
Occidiofungin Bioactivity and Nutrient Deprivation
To expand on the impact nutrient availability had on occidiofungin’s bioactivity,
mid-log cells were exposed to occidiofungin in synthetic defined media lacking glucose,
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nitrogen, or phosphate. As seen in Figures 3.8 and 3.9, cell viability after occidiofungin
exposure varied greatly depending on the starvation conditions in which cells were
placed. Mid-log cells exposed to glucose-deprivation conditions appeared to be more
susceptible to occidiofungin, while those in SD media lacking phosphate were resistant.
Nitrogen availability did not appear to impact occidiofungin bioactivity.

Figure 3.8

Cellular response of mid-log cells to occidiofungin is dependent on nutrient
availability and is nutrient-specific

CFU Assay depicting cell viability of mid-log cells post-exposure to 1.0µg/mL
occidiofungin (+occ) in Synthetic Defined (SD) media as well as SD media lacking
Glucose (No Carbon), Nitrogen, or Phosphate. Representative graph shown (n=2).
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Figure 3.9

The susceptibility of mid-log cells varies in normal and starvation
conditions

Spotting assay depicting differences in susceptibility at 2 hours post-exposure to 1µg/mL
occidiofungin (+occ), or vehicle control (Ø), under normal and various starvation
conditions. SD; Synthetic Defined. Representative image shown (n=2).
Glucose Starvation and Rapamycin-Induced Inhibition of the Nutrient Sensing
Complex, TOR1C
The largest difference in susceptibility was the response to glucose-starvation
conditions. The stark decrease in viable cells seen in the absence of glucose may be due
to the abrupt inhibition of protein synthesis seen in cells whose extracellular glucose
source is removed (Ashe, De Long and Sachs 2000). To evaluate whether this translationinhibiting response to the absence of glucose is what resulted in such drastic differences,
we compared the cellular response to occidiofungin under a chemically induced
starvation response with the response to the absence of glucose.
To further characterize the cellular response to occidiofungin in glucose-starved
cells, we took advantage of rapamycin’s TOR inhibiting capabilities in a CFU assay
utilizing media both with and without glucose in the presence of rapamycin and
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occidiofungin. To initially confirm that rapamycin blocked TOR signaling, we measured
changes in Cit2p levels by Western blot analysis. Previous work has shown that
rapamycin induces expression of CIT2, a finding that was repeatable (Giannattasio, et al.
2005). As shown in Figure 3.10, mid-log cells exposed to 0.1µg/mL rapamycin showed a
significant increase in Cit2p levels within 20 minutes of addition. Occidiofungin is
unlikely to interfere with signaling downstream of Tor1C, as Cit2p expression was still
increased in the presence of both rapamycin and occidiofungin (data not shown).

Figure 3.10

Expression of Cit2p:HA3 increases upon exposure to 0.1µg/mL rapamycin
but not after exposure to 1.0µg/mL occidiofungin

Expression of Cit2p:HA3 increased within 20 minutes of exposure to rapamycin. Total
cell protein extracts (equivalent to 0.1 OD600) were separated by SDS-PAGE. Protein
detection by western blot was conducted using anti-HA to detect Cit2p and anti-Pgk1p to
detect Pgk1p. Pgk1p was included to confirm equal loading. Representative image shown
(n=2).
The resulting data (Figure 3.11) holds strong implications for the role of the cell’s
response to nutrient availability in occidiofungin’s varying bioactivity. Cells exposed to
both rapamycin (at 0.1µg/mL) and occidiofungin (1.0µg/mL) experienced a much greater
decline in cell viability in both media types than with occidiofungin alone, though this
effect was more pronounced in media lacking glucose.
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Figure 3.11

Rapamycin enhances the effects of occidiofungin

CFU data of mid-log cells exposed to 0.1µg/mL rapamycin (+rap) and 1.0µg/mL
occidiofungin (+occ) in the presence (SD; synthetic defined) and absence (SD-g) of
glucose. Representative graph shown (n=2).
Inhibition of Cytosolic and Mitochondrial Protein Synthesis
In addition to rapamycin, cycloheximide was also used to pharmacologically
assess occidiofungin bioactivity. We subjected mid-log cells to 25µg/mL cycloheximide
and 1.0µg/mL occidiofungin and found a marked decrease in the ability of cultures to
recover from occidiofungin exposure (Figure 3.12). However, because cells exposed to
cycloheximide experience no growth, it remained unclear if the difference was because
the cells’ inability to complete the cell cycle simply revealed total cell death unmasked by
the usual culture recovery, or if they are due to other factors.
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Figure 3.12

Cycloheximide addition inhibits the culture's recovery from occidiofungin

Graph depicting the effect of 25µg/mL cycloheximide (+cxm) on the susceptibility of
cells to 1.0µg/mL occidiofungin (+occ) in SD (synthetic defined) media as compared to
occidiofungin treatment in SD-glucose media. Representative graph shown (n=2).
To this end, it was decided that pre-treating cells with cycloheximide for 30
minutes would aid in elucidating the cause of this effect, as the effects of translation
inhibition would be established in pre-treated cells. Our data (Figure 3.13) demonstrates
that pre-treatment with cycloheximide actually provides a protective effect against
occidiofungin, as opposed to the synergistic effects seen when cells were concurrently
exposed to both drugs.
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Figure 3.13

Pre-treatment with cycloheximide is protective against occidiofungin,
while simultaneous treatment has synergistic effects

Graph illustrating the protective effects of 30 minutes of pre-treatment (T=-30’) with
25µg/mL cycloheximide (cxm) and the synergistic impact of simultaneous treatment
(n=5) with 1µg/mL occidiofungin (+occ). Representative graph shown (n=3).
In addition to cycloheximide, the effects of pre- and concurrent treatment with
chloramphenicol were also evaluated with respect to occidiofungin. As the
mitochondrion is a significant producer of ROS in the cell, we hoped that utilizing this
mitochondrial translation inhibitor might aid in elucidating whether mitochondria might
play a role in occidiofungin-induced cell death. Further, due to the mitochondrial
repression effects induced by glucose, we were also interested in investigating the effects
of chloramphenicol when mitochondrial activity was not repressed (Mian, Küenzi and
Halvorson 1973). In this regard, the impact of chloramphenicol was tested in synthetic
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media containing 2% glucose and compared to the same media containing 2% raffinose
as the carbon source (Figure 3.14).

Figure 3.14

Pre-treatment with chloramphenicol (chl) had little impact on
occidiofungin bioactivity, but is synergistic when added simultaneously
with occidiofungin

Graph demonstrating the effect of pretreatment (T= -30’) with 60µg/mL chloramphenicol
(chl) versus concurrent treatment with 1.0µg/mL occidiofungin (+occ) in synthetic media
containing glucose (no marker outlines) as compared to synthetic media containing
raffinose (outlined markers) as a carbon source. Representative graph shown (n=2).
Our results indicate that chloramphenicol treatment at 60µg/mL in conjunction
with 1.0µg/mL occidiofungin treatment appears to exhibit synergistic effects in synthetic
media with glucose as well as in media with raffinose as a carbon source. In both media
types, pre-treatment of cells with chloramphenicol may have slight protective effects,
though this effect appears to be minimal.
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Phosphate Deprivation and Occidiofungin Activity
With a small number of factors identified that increase susceptibility, we shifted
our focus to the resistance demonstrated in phosphate deprivation conditions. We selected
two primary PHO pathway deletion mutants, ∆pho4 and ∆pho80, to aid in characterizing
the resistance response that occurs under phosphate starvation conditions. As shown
below in Figures 3.15 and 3.16, the ∆pho4 mutant was resistant to occidiofungin
compared to both the wild type and ∆pho80 cells under phosphate replete and deplete
conditions, while ∆pho80 exhibited only slightly greater susceptibility than the wild type.

Figure 3.15

Occidiofungin is more effective against pho4 mutants than pho80 mutants
and the wild type in SD media

Values for the average % ∆CFU (n=3) after occidiofungin exposure in SD media for pho4
and pho80 mutants were calculated by taking the mean change in the CFU value between
T0 and subsequent time points. The average of this value over 3 trials was then used to
represent the average % change in CFU values for each strain after occidiofungin
exposure, with respect to time.
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Figure 3.16

Occidiofungin is more effective against pho4 mutants than pho80 mutants
and the wild type in SD media lacking phosphate

Values for the average % ∆CFU (n=3) after occidiofungin exposure in SD media lacking
phosphate for pho4 and pho80 mutants were calculated by taking the mean change in the
CFU value between T0 and subsequent time points. The average of this value over 3 trials
was then used to represent the average % change in CFU values for each strain after
occidiofungin exposure, with respect to time.
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CHAPTER IV
SUMMARY

Discussion of Results
The need for novel antifungal therapies has never been more apparent. The
increasing significance of IFIs in healthcare and rising prevalence of resistance
development in fungal pathogens makes the discovery and characterization of novel
antifungal therapies ever important. Occidiofungin’s unique and broad-spectrum activity
against fungi, limited toxicity to mammalian tissue, and chemical stability support its
candidacy for further investigation as a useful antifungal in clinical therapy. Though its
mechanism of action is not fully understood, we have identified a number of cellular and
environmental factors that either enhance or reduce occidiofungin’s effectiveness against
Saccharomyces cerevisiae.
Unfortunately, the nature of conducting CFU assays using dose-dependent
drugs makes statistical analysis of the data difficult. Even slight variations in starting
cell culture density appear to have an impact on the degree to which differences in
sensitivity are detected. Thus, graphs exemplifying general trends in susceptibility
consistent across multiple trials were used to illustrate results.
We have demonstrated that yeast in a starvation-induced quiescent state are
resistant to the effects of occidiofungin and retain this resistance until environmental
stimuli (specifically, the availability of a carbon source) induce their reentry into the cell
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cycle, after which they become susceptible to the drug. This suggests that occidiofungin
may be less effective in quiescent cells or that susceptibility may require active
growth. Further, this sustained resistance allows us to deduce that occidiofungin must
require active transport processes in order to exhibit its effects. If occidiofungin were
able to interact with the quiescent yeast in depleted media in a manner that promoted
its eventual import into the cell (via receptor binding or non-specific interactions with
the outer cell wall), these cells are likely to have succumbed to occidiofungin upon
transfer to YPD agar and the data would have reflected cell death.
The potential for genes involved in quiescence to be effective targets of
antifungals seems unlikely. However, these findings are significant due to the metabolic
characteristics that quiescent yeast share in common with slow growing cells, which are
often found within biofilms, and provides support for the notion that active cellular
processes may be required for occidiofungin’s import and activity. For drugs that rely on
active cellular processes to exhibit their activity, one would expect their efficacy to
decrease as cell metabolism slows. This has been demonstrated in one study aimed at
characterizing the contribution of slow growth rates to amphotericin B and azole
resistance in fungal biofilms. Though it was found that the antifungal resistance of
biofilms is not solely attributable to the slow growth of its cells, their findings did
indicate that planktonic cells at very low growth rates (a trait the authors noted was
also found in the innermost cells of fungal biofilms) exhibited similar resistance
(Baillie and Douglas 1998). For these reasons, it was decided that the retained ability
to respond to stimuli and abundant characteristics of slow growth found in quiescent
cells may suffice as a preliminary model to aid in determining whether
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occidiofungin’s activity is reliant on active cellular processes. However, our results
are not conclusive with regards to the impact of growth rate on occidiofungin
susceptibility, and these findings should be confirmed through the use of a chemostat
to manipulate growth conditions before characteristics on the susceptibility of slow
growing planktonic cells can be reported.
Further, we have shown that transcriptional responses to starvation for specific
nutrients have variable impacts on occidiofungin bioactivity. The absence of glucose, the
key signal in regulating normal cellular processes (particularly gene expression as it
relates to growth), drastically increases susceptibility to occidiofungin (Ashe, De Long
and Sachs 2000). This effect is presumably due to the starvation-induced alteration of the
cell’s transcriptional profile and abrupt cessation of translation, and not due specifically
to the absence of glucose. Knowing this, the possibility arises that the increased
susceptibility to occidiofungin in the absence of glucose may be due the cells’
inability to synthesize the proteins necessary to respond to and repair cellular damage
caused by occidiofungin. This would result in more rapid cell death than in cultures
able to compensate for some of the stresses.
This hypothesis is supported by the synergistic effects seen under rapamycininduced TOR1C inhibition (falsely interpreted by the cell as starvation), as these effects
were observed in both the presence and absence of glucose. With regards to previously
published research concerning the concurrent use of rapamycin and antifungals, the data
is inconclusive. One report by Dannaoui, et al. indicated that synergistic effects between
rapamycin and the antifungals amphotericin B, itraconazole, posaconazole, and
ravuconazole were present in 70%, 50%, 40%, and 30% of the 10 zygomycete isolates
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tested, respectively, while antagonistic effects were observed with itraconazole in 20% of
isolates and with ravuconazle in 10% (Dannaoui, Schwarz and Lortholary 2009). These
results are in contrast to data reported later by Narreddy, et al., which demonstrated
“consistent and significant antagonism” with rapamycin and posaconazole in most of the
28 clinical zygomycete isolates tested. This research group attributed these contrasting
findings to the different endpoint readings utilized in the two studies, as Narreddy, et al.
used the CLSI M38-A2 standard of 100% inhibition as the endpoint, while Dannaouri, et
al. used an endpoint of 50% inhibition (Narreddy, et al. 2010). The utility of rapamycin
as a candidate for combination therapy is therefore unresolved, and additional research
will be necessary to definitively characterize these effects.
Notably, a mutant strain lacking TOR1 showed no change in MIC value compared
to a wild type strain (data not shown), a result seemingly contrary to data reported here.
We suspect this is likely due to sensitivity differences between MIC and CFU assays
discussed previously and not an indication of conflicting results, as these discrepancies
have been demonstrated in our lab before (data not shown). As CFU assays are a more
accurate analysis of cell number as it relates to susceptibility, we suggest reevaluating the
∆tor1 strain using a CFU assay. Regardless, there is significant evidence for the role of
glucose starvation-induced changes in transcriptional regulation in the increased
susceptibility we demonstrated.
We also demonstrated seemingly conflicting trends in the effects of
cycloheximide-mediated inhibition of cytosolic translation and chloramphenicol-induced
inhibition of mitochondrial translation. Cycloheximide (cxm) is a standard tool used in
molecular biology as it inhibits the elongation phase of eukaryotic translation by
53

interfering with the translocation step. This is useful for the general analysis of
mRNA translation and ribosome profiling, but was also helpful in our case, as it
allowed us to determine that active translation is necessary for surviving
occidiofungin exposure (Gerashchenko and Gladyshev 2014). Chloramphenicol (chl),
in contrast, is a bacteriostatic translation inhibitor that functions by inhibiting the
peptidyl transferase activity of prokaryotic and mitochondrial ribosomes, thereby
preventing protein chain elongation. Chloramphenicol does not interfere with
cytosolic translation. We demonstrated that concurrent addition of these inhibitors with
occidiofungin resulted in greater cell death than samples that received occidiofungin
alone. This suggests that translation may be required to abrogate cellular damage due to
occidiofungin exposure. When cells were exposed to occidiofungin after being pretreated with these drugs, however, the effects were opposite: cells were somewhat
protected. In the case of cycloheximide pre-treatment, it is possible that the lack of
growth under such conditions could play a role in this antagonistic effect. Given that
occidiofungin activity appears to be reliant on active cellular processes, it is also possible
that, while cells enduring cycloheximide-induced translation inhibition are indeed still
active, either occidiofungin’s transport into the cell or its mechanism of inducing cell
death may be dependent on processes heavily influenced by the rate of new protein
synthesis. In support of the latter conclusion, previous research has indicated that
cycloheximide-induced translation inhibition prevents both apoptotic chromatin
condensation and DNA fragmentation. It was demonstrated that treatment with 15µg/mL
cycloheximide, a concentration sufficient to reduce the rate of cytosolic translation by
>92%, for 30 minutes prior to hydrogen peroxide exposure provided protective effects
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against oxidative-stress, thereby preventing the cell from inducing its own cell death
(Madeo, et al. 1999). The lack of growth seen in the cycloheximide pre-treatment
control (not exposed to occidiofungin) not only supports the active growth
requirement for occidiofungin’s activity, but also indicates a potential disadvantage of
combination therapy using cycloheximide and occidiofungin, as any number of
factors impacting the utility of the two compounds could drastically alter
occidiofungin’s effectiveness.
With regards to mitochondrial translation inhibition, pre-treatment with
chloramphenicol had little impact on cell death due to occidiofungin, while
simultaneous treatment resulted in increased cell death. One implication of these
results is that the mitochondria may not play a direct or significant role in
occidiofungin’s bioactivity. Rather, it is likely that the production of ROS due to
normal or increased mitochondrial activity may only enhance the degree to which the
cell experiences oxidative stress, potentially hastening an apoptotic response. The
resistance to occidiofungin seen in cells under anaerobic conditions supports this
conclusion (Emrick, et al. 2013).
Finally, we demonstrated that cells exhibit resistance to occidiofungin under
phosphate-deprivation conditions, and examined this resistance further by evaluating
two phosphate signaling pathway mutants and their respective susceptibilities to
occidiofungin. Phosphate signaling in budding yeast has been well characterized and
is mediated by a subset of genes in what is known as the PHO pathway. This pathway
utilizes the phosphorylation of the transcription factor Pho4p to control its
localization in the cell and therefore its access to its effector genes in the nucleus. In
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the presence of phosphate, the Pho80p-Pho85p complex phosphorylates Pho4p,
preventing its entry into the nucleus. Under phosphate deprivation conditions, this
complex is unable to phosphorylate Pho4p, which consequently results in its
translocation to the nucleus where it upregulates the expression of phosphatase and
phosphate scavenging genes (Mouillon and Persson 2006). Due to the role of Pho80p
in phosphate signaling, one would have expected the ∆pho80 mutant to display a
resistance profile similar to that of cells placed into phosphate starvation conditions,
as the Pho80p-Pho85p complex would no longer exist to phosphorylate Pho4p,
resulting in a perpetual cellular response to phosphate starvation regardless of actual
nutrient availability. On the other hand, the ∆pho4 mutant in phosphate starvation
conditions would be expected to behave as the wild type did in SD complete media
due to the inability of the strain to respond to phosphate deprivation. Our results,
however, were in direct contrast to our hypothesis of the impact of occidiofungin on these
PHO pathway mutants. With regards to the pho4 mutant, research by Hu et al identified a
number of genes whose transcriptional regulation was altered in strains deleted for pho4
(Hu, Killion and Iyer 2007). We suspect these transcriptional changes may well be
responsible for the resistance effects seen in our study and that genes within this dataset
would be interesting candidates for future pursuit. Regardless, we did identify the
deletion of PHO4 as a contributor to occidiofungin resistance, the mechanism of
which could be resolved through an analysis of the transcriptional changes that occur
in the cell upon deletion of this transcription factor.
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Directions for Future Research
The role of occidiofungin in the arsenal of modern antifungal therapies has yet to
be determined, as there is much to be discovered about its activity in the fungal cell.
Through our studies, we have identified a number of potential avenues in which
information about occidiofungin’s mechanism of action could be further characterized.
First, altered transcriptional profiles in response to starvation conditions are clear
effectors of occidiofungin bioactivity. An investigation of the literature associated with
starvation response and TOR1C inhibition, and the inclusion of a CFU analysis of yeast
deleted for TOR1, could yield promising indicators of where this novel antifungal
functions in the cell. Further, as we have established that active cellular processes may be
required for its import and activity, studies evaluating the effects of slow growth rates
and the role of various transport mechanisms of yeast on occidiofungin’s bioactivity
could prove worthy of inquiry.
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